WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413115
CAS#: 14613-30-0
Description: Magnesium clofibrate is a magnesium salt formulation of clofibrate, an aryloxyisobutyric acid derivate with antihyperlipidemic activity.
Hodoodo Cat#: H413115
Name: Magnesium clofibrate
CAS#: 14613-30-0
Chemical Formula: C20H20Cl2MgO6
Exact Mass: 450.05
Molecular Weight: 451.570
Elemental Analysis: C, 53.20; H, 4.46; Cl, 15.70; Mg, 5.38; O, 21.26
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Magnesium clofibrate; UR112; UR-112; UR 112
IUPAC/Chemical Name: magnesium 2-(4-chlorophenoxy)-2-methylpropanoate
InChi Key: SYMULEBHDFQHNX-UHFFFAOYSA-L
InChi Code: InChI=1S/2C10H11ClO3.Mg/c2*1-10(2,9(12)13)14-8-5-3-7(11)4-6-8;/h2*3-6H,1-2H3,(H,12,13);/q;;+2/p-2
SMILES Code: CC(Oc1ccc(Cl)cc1)(C([O-])=O)C.CC(Oc2ccc(Cl)cc2)(C([O-])=O)C.[Mg+2]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 451.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Paltauf F, Pristautz H, el Eisch IA. Pharmakokinetik einer Kombination von Magnesium-Chlorphenoxy-Isobutyrat und dem Hexanikotinsäureester des meso-Inosits [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate]. Acta Med Austriaca. 1977;4(3):120-4. German. PMID: 930544.
2: Krahling JB, Tolbert NE. Peroxisomal beta-ketothiolase. Arch Biochem Biophys. 1981 Jun;209(1):100-10. doi: 10.1016/0003-9861(81)90261-7. PMID: 7283429.
3: Nieper HA. Capillarographic criteria on the effect of magnesium orotate, EPL substances and clofibrate on the elasticity of blood vessels. Agressologie. 1974;15(1):73-7. PMID: 4440820.
4: Lazarow PB. Rat liver peroxisomes catalyze the beta oxidation of fatty acids. J Biol Chem. 1978 Mar 10;253(5):1522-8. PMID: 627552.
5: Capuzzi DM, Margolis S. Metabolic studies in isolated rat liver cells. I. Lipid synthesis. Lipids. 1971 Aug;6(8):601-8. doi: 10.1007/BF02531143. PMID: 4255318.
6: Maragoudakis ME. On the mode of action of lipid-lowering agents. VI. Inhibition of lipogenesis in rat mammary gland cell culture. J Biol Chem. 1971 Jun 25;246(12):4046-52. PMID: 4327196.
7: Gupta JD, Gruca M, Ablett W. Effect of other drugs and chemicals on the degradation of aspirin in vitro: possible extrapolation to in vivo metabolism of aspirin. Eur J Drug Metab Pharmacokinet. 1979;4(2):103-8. doi: 10.1007/BF03189409. PMID: 488131.
8: Kather H, Simon-Crisan G, Vogt B, Simon B. Effects of clofibrate on the human fat cell adenylate cyclase system. Horm Metab Res. 1977 Jul;9(4):300-4. doi: 10.1055/s-0028-1093517. PMID: 196990.
9: Irsigler K, Flegel U, Kühn P, Schubert H, Iván E, Biro L, Székely L. Verbessert Magnesium-Orotat die Wirkung lipidsenkender Pharmaka [Does magnesium- orotate improve the effect of lipid lowering drugs?]. Int J Clin Pharmacol. 1973 Aug;8(1):85-95. German. PMID: 4727450.
10: Ikemoto T, Endo M. Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. Br J Pharmacol. 2001 Oct;134(4):719-28. doi: 10.1038/sj.bjp.0704306. PMID: 11606311; PMCID: PMC1573000.
